Anti-GITR agonistic antibody therapy reprograms Tregs into anti-tumor Th1-like CD4+ T cells with the expression of IFNγ and the acquisition of cytotoxic activity against tumor cells and converts the immunosuppressive TIME into an immunostimulatory milieu causing tumor regression [37]. The gene discussed is TNFRSF18; the disease is neoplasm.